Johnson & Johnson (JNJ) said Wednesday that it has received approval from the US Food and Drug Administration for Imaavy, a treatment for generalized myasthenia gravis.

The treatment, also known as nipocalimab-aahu, has the potential to provide lasting disease control in adults and pediatric patients aged 12 and up who test positive for anti-acetylcholine receptor or anti-muscle-specific kinase antibody, the company said.

The company said applications for the approval of nipocalimab are being reviewed by regulatory authorities globally.